Home
About
Overview
Sharing Data
ORCID
Help
History (25)
Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.
Health: The weighty costs of non-caloric sweeteners.
Public Attitudes and Knowledge About Youth Sports Participation and Concussion Risk in an Urban Area.
Clinical management of herpes simplex virus infections: past, present, and future.
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
See All 25 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021 01 19; 2(1):100186.
View in:
PubMed
subject areas
Antigens, Neoplasm
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Drug Design
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
Molecular Targeted Therapy
Mutation
Proto-Oncogene Proteins p21(ras)
Signal Transduction
authors with profiles
Ravi Salgia